对早泄患者而言，性爱时间哪怕只延长了一秒钟，都是天大的事。据美国“健康日”网站4月7日报道，一项针对300名欧洲男性的研究发现，一种新型的“延时喷雾”能帮助早泄男性推迟射精时间，将性爱全过程延长6倍。
据了解，这些男性都在临床上被诊断为早泄。他们被分为两组，一组在性爱前5分钟使用安慰剂喷雾，另一组使用新型PSD502喷雾(含有7.5毫克利多卡因和2.5毫克丙胺卡因)。随后，他们需要用秒表记录下单次性爱时长，以插入阴道为开始，射精为结束。
3个月后，研究人员发现使用PSD502喷雾的人，仅高潮时间就从0.6秒延长至3.8秒，性爱过程是原来的6.3倍。其中，90%的人可以自主控制射精时间，推延到1分钟以后，74%的人可以坚持2分钟以上。在研究开始前，只有20%的人对性生活满意，而3个月后，62%的人认为自己的性生活“很好”或“非常好”。
这种早泄喷雾运用了混合制剂的理念，我国在早泄治疗中，也常会用到类似药物。“早泄药物主要是通过局部麻醉阴茎表面皮肤，来达到治疗效果。混合制剂的突出特点就是促进渗透，起效快，使表面麻醉的效果更充分。一般使用后，性爱时间可以延长3—10倍，有效率达50%—80%。”传统的早泄外用药物使用后，还需要清洗、擦拭阴茎，以免药物残留。而混合制剂渗透性好，挥发也快，残留物少，不太影响女性的性感受，因此更建议使用。
Phase 3 study of PSD502 for treatment of premature ejaculation (PE) Sciele Pharma and Plethora Solutions announced that a second Phase 3 study of PSD502 for the treatment of premature ejaculation (PE) has met all co-primary endpoints of Intra-vaginal Ejaculation Latency Time (IELT) and Index of Premature Ejaculation ((IPE) Ejaculatory Control, Sexual Satisfaction and Distress domains).
This trial was the second of two, multi-center, randomized, double blind, placebo-controlled efficacy studies where patients were treated for a 12-week period with an optional open-label phase of up to nine months. Entirely consistent with the first study, analyses show that PSD502 produced a highly clinically and statistically significant increase from baseline in all co-primary study endpoints.
The IELT was increased at least six-fold with PSD502 when compared to baseline (p<0.0001). There was a five-point difference between PSD502 and placebo in the IPE domains for ejaculatory control and sexual satisfaction (p<0.0001), where a two-point difference is considered clinically significant. There was a 2.5-point difference between PSD502 and placebo in the IPE domain for Distress (p<0.0001), where a two-point difference is considered clinically significant. As a secondary endpoint, partner satisfaction was also found to be considerably greater with PSD502 than placebo. The incidence of serious adverse events and overall side
effects was similar in the PSD502 and placebo group. Overall, PSD502 was well tolerated and there were no systemic adverse events.
PSD502 is a proprietary formulation of two marketeddrugs,lidocaineandprilocaine, dispensed by a metered dose aerosol.